Evaluation of effectiveness and safety of the multizone NeVa stent retriever for mechanical thrombectomy in ischemic stroke.

PURPOSE

This study aimed to evaluate the effectiveness and safety of the NeVa stent retriever as first- and second-line device for mechanical thrombectomy in acute ischemic stroke.

METHODS

In this retrospective single-center study, all consecutive patients that underwent mechanical thrombectomy with NeVa stent retriever as first- or second-line device due to intracranial vessel occlusion with acute ischemic stroke between March and November 2022 were included.

RESULTS

Thirty-nine patients (m=18, f=21) with a mean age of 69.9 ± 13.3 years were treated with the NeVa stent retriever. NeVa stent retriever was used as first-line device in 24 (61.5%) of patients and in 15 (38.5%) as second-line device. First-pass rate (≥mTICI 2c) of NeVa stent retriever was both 66.7% when used as first- or second-line device. Final recanalization rate including rescue strategies was 92.3% for ≥mTICI2c and 94.9% for ≥mTICI2b. No device-related minor or major adverse events were observed. A hemorrhage was detected in 33.3% of patients at 24h post-thrombectomy dual-energy CT, of which none was classified as symptomatic intracerebral hemorrhage. NIHSS and mRS improved significantly at discharge compared to admission (p<0.05).

CONCLUSION

The NeVa stent retriever has a high effectivity and good safety profile as first- and second-line device for mechanical thrombectomy in acute ischemic stroke.